SCHUMER, GILLIBRAND, MORELLE ANNOUNCE UNIVERSITY OF ROCHESTER RECEIVES PRESTIGIOUS FEDERAL CANCER CENTER DESIGNATION FOR WILMOT CANCER INSTITUTE
Designation Will Boost Clinical Opportunities, Reputation, And Research $$ For U Of R’s Wilmot Cancer Institute, Upstate NY’s Largest Cancer Provider, Which Has Made Significant Cancer Discoveries And Treats Thousands Each Year
Schumer, Gillibrand, Morelle All Urged NCI Director To Give This Designation, And Schumer Personally Called Former NIH Director To Advocate For It
Schumer, Gillibrand, Morelle: Cancer Center Designation Will Boost Fed Support For Wilmot’s Cancer Research And Treatment
U.S. Senator Chuck Schumer, U.S. Senator Kirsten Gillibrand, and U.S. Congressman Joe Morelle today announced the University of Rochester’s Wilmot Cancer Institute has received the prestigious federal Cancer Center designation from the National Cancer Institute. The Wilmot Cancer Institute is Upstate New York’s largest and busiest cancer provider, and conducts medical research and treats cancer patients.
“I am proud to announce that following my advocacy, Rochester’s Wilmot Cancer Institute has received the prestigious federal Cancer Center designation. This designation is the ultimate recognition for the world-class staff here in Rochester that they are leading America in cancer research and through their work will make new breakthroughs in cancer treatment and save lives,” said Senator Schumer. “The Wilmot Cancer Institute is Upstate New York’s largest cancer provider, and this designation is a national spotlight to uplift them as one of the top cancer research centers in the country. It means additional funding, better support for our doctors & nurses, increasing clinical opportunities, and enhancing the center’s ability to recruit cancer investigators. I personally called the former NIH director to advocate for this designation last fall and will always fight to ensure New York’s medical researchers have the resources they need to provide the medical care New Yorkers deserve.”
“The designation of the Wilmot Cancer Center as a federal Cancer Center is a testament to the groundbreaking clinical research, lifesaving treatments, and exceptional patient care that it provides for patients across Upstate New York,” said Senator Gillibrand. “This designation will unlock up to $10 million in additional funding, which will enhance the Wilmot Cancer Center’s ability to advance scientific discovery and improve access to high-quality care for cancer patients. I am honored to have worked alongside Senator Schumer and Representative Morelle to secure this designation, reinforcing the Wilmot Cancer Center’s leadership in the fight against cancer and its commitment to medical excellence, and I extend my congratulations to the University of Rochester for this prestigious designation.”
"The Wilmot Cancer Institute’s designation as a National Cancer Institute is an historic achievement—one that cements its place among the nation’s premier cancer research and treatment centers. This recognition is not just about a title; it is a testament to the relentless dedication of the doctors, researchers, and caregivers who bring hope to families in their most challenging moments,” said Congressman Joe Morelle. “It is deeply moving to see the team that cared for my daughter, Lauren—and so many other families like ours—receive this nationally-recognized symbol of excellence. I’m grateful to the many partners whose advocacy helped make this a reality, and most importantly, to the dedicated team at Wilmot fighting tirelessly for a cancer-free future.”
“Today is a monumental day for the University of Rochester and the Wilmot Cancer Institute—one that is more than 10 years in the making,” said University of Rochester President Sarah Mangelsdorf. “This National Cancer Institute designation allows us to forge a new path to removing the burden of cancer in our community and throughout upstate New York. From here, our goals are to continue making the discoveries right here in Rochester that advance our understanding of cancer, improve the effectiveness of current therapies, and through research and clinical trials provide new life-saving and life-extending treatments to all of our patients in need. This couldn’t have happened without the strong bipartisan support and efforts from our Congressional delegation. I want to profoundly thank Sen. Chuck Schumer for his unwavering support to the University and the Rochester community that has helped us reach this milestone. I also want to thank Rep. Joe Morelle for his leadership and Senator Gillibrand, Rep. Langworthy and Rep. Tenney for their strong support.”
The Wilmot Cancer Institute is Upstate New York’s largest cancer provider, supporting 27 counties with a population of more than 3.2 million people. This region, which lacks an NCI-designated cancer center, is one of the largest underserved areas in the nation in terms of access to cutting-edge cancer research and treatment. There is strong bipartisan support for boosting funding for the Wilmot Cancer Institute, which has made significant cancer research discoveries and treats thousands of cancer patients each year.
Wilmot Cancer Institute, celebrating its 50th anniversary, is New York’s busiest cancer center outside of NYC, serving a 27-county region with over 3.2 million people, a geographic area larger than Vermont and New Hampshire combined. It operates across 13 locations in a unique catchment area that lacks any other NCI-designated cancer center and faces significantly higher cancer incidence and mortality rates than the rest of the state and nation. If this region were its own state, it would rank second in the country for cancer incidence behind Kentucky. The region includes rural communities and areas of high poverty, including Rochester, ranked third in poverty among the 75 largest U.S. metropolitan areas. Additionally, 12 counties in this region are designated as part of Appalachia, further limiting healthcare access, and it has the largest per-capita Deaf population in the country, requiring specialized approaches to cancer care. Cancer disparities by geography, race, and ethnicity are stark, with access challenges and higher rates of smoking, obesity, and inactivity.
Over the past eight years, Wilmot Cancer Institute has embarked on a bold strategic plan with the goal of becoming an NCI-designated cancer center. Wilmot has significant institutional commitment from the University of Rochester and broad community support and has been successful in recruiting over 30 world-class scientists, doubling accruals to clinical trials, doubling external funding for cancer research, and establishing impactful Community Outreach and Engagement, and Cancer Research Training and Education programs resulting in an elite cancer center worthy of NCI designation.
The Cancer Center designation provides additional research funding, increases clinical opportunities and patient volume, and enhances ability to recruit cancer investigators, among other benefits. In addition to federal funding, the University of Rochester has committed over $100 million in institutional investment to strengthen Wilmot’s infrastructure, research capabilities, and workforce recruitment. Based on a based on an estimate from the Center for Governmental Research, the designation is also expected to generate nearly 1,900 new jobs, create $194 million in labor income, and contribute $15 million annually in income and sales tax revenue—making it a major economic driver for the region.
The members of the New York Congressional delegation – Senators Schumer and Gillibrand, Congressman Morelle, Congressman Higgins, Congresswoman Stefanik, Congresswoman Tenney, Congressman Langworthy, and Congressman Molinaro – in fall 2023 wrote a bipartisan letter to former Acting Director of the National Cancer Institute Douglas R. Lowy advocating for this designation, and Schumer also personally called former NIH Director Dr. Monica Bertagnolli about the University of Rochester’s application. During his direct advocacy, Schumer emphasized that Wilmot’s service area has one of the highest cancer burdens in the country and is one of the largest areas nationwide without access to an NCI-designated cancer center. He underscored how the NCI designation would help boost clinical trials, improve research capacity, and help ensure Upstate New York’s underserved populations receive the best possible cancer care. The lawmakers explained that the Wilmot Cancer Institute has met rigorous standards for research, education, and cancer prevention and patient care and presents a significant opportunity for continued growth and expansion of federally supported cancer research.
The New York Congressional Delegation’s letter to former Acting Director of the National Cancer Institute Douglas R. Lowy can be found HERE or below:
Dear Dr. Lowy:
We write in strong support of the University of Rochester’s Wilmot Cancer Institute’s A1 revised application for a National Cancer Institute (NCI) Cancer Center Support Grant. Wilmot has established itself as the leader in cancer care and research in our region and is poised to join other NCI designated centers.
Last year, we were disappointed to learn that, despite presenting a strong application, the significant needs in our districts, and receiving an excellent score that was better than several of the most recent new Cancer Center Support Grants approved in other states, Wilmot did not receive a Cancer Center Support Grant (CCSG). However, the University of Rochester remains steadfastly committed to the goal of NCI designation, and over the past two years, Wilmot has worked to address the feedback received from the NCI review committee and strengthen their application. The University has articulated this commitment in its strategic plan, including a financial pledge of over $100 million to Wilmot, and plans to expand the cancer research footprint with additional physical space over the next five years. With NCI designation and the University’s significant commitment, Wilmot will continue to push the frontiers of cancer science, enhance community engagement, and expand collaborations, including with Roswell Park Comprehensive Cancer Center, the nearest NCI center and a frequent research partner.
The Wilmot Cancer Institute is New York’s largest cancer provider outside of New York City, providing care for a catchment area that includes 27 counties with a population of more than 3.2 million people. As Upstate New York’s largest cancer center, Wilmot’s 159 oncology physicians and 336 nurses treated over 5,500 cancer cases across 14 regional locations in 2021. Over its nearly 50-year history, Wilmot’s research has led to significant advances in oncology standards of care and has helped lead the way in two of the top five cancer discoveries of the past half century as identified by the American Society of Clinical Oncology: utilizing virus-like particles to create the first approved HPV vaccine and carrying out clinical trials to demonstrate the effectiveness of anti-emetic therapy in patients undergoing chemotherapy. With over $30 million in annual sponsored research funding – including over $14 million in annual direct funding from NCI – Wilmot is leveraging its longstanding strengths within a framework of collaboration through three multidisciplinary programs that study cancer biology, the tumor environment, and cancer prevention and toxicity management.
Data shows that cancer incidence and mortality is significantly higher in the region that Wilmot Cancer Institute serves, as compared to the rest of New York State and the nation. This catchment area is the equivalent to the size of the States of Vermont, New Hampshire, and Rhode Island combined and, if considered as a state, would have the second highest cancer incidence in the nation behind only the State of Kentucky. Approximately one-third of people in this catchment area live in rural communities that are underserved, understudied, and negatively impacted by social factors. Of the 27 counties in this area, 26 have a higher poverty level than the U.S. average, including the City of Rochester, which ranks third in overall poverty among the nation's 75 largest metropolitan areas, and 12 of the 14 counties that are part of Appalachian portion of New York State. Furthermore, there are drastic and unacceptable cancer disparities by geography, race, and ethnicity among this population. Among other indices of disparity, individuals in Wilmot’s catchment area experience longer delays between diagnosis and the onset of treatment, and higher rates of smoking, obesity, and physical inactivity.
While New York has seven other NCI-designated centers, we want to stress that the catchment area Wilmot will support is not covered by another existing center representing a large geographic portion of New York State, and has the support of Roswell Park, the closest and only other NCI center in upstate New York. As such, Wilmot has strong bipartisan support from not only the Congressional delegation, but Governor Hochul and the NYS Legislature. Given the size of this region and scope and severity of disease, investment in Wilmot’s research infrastructure by the NCI through a Cancer Center Support Grant would allow Wilmot to expand its efforts to reduce the significant burden of cancer on our constituents by guiding efforts and attention where the need is greatest, collaborating with underserved communities to better understand and resolve cancer disparities, providing greater access to clinical trials and innovative treatments, and in turn, offering valuable data to NIH on a unique and currently uncaptured population that would have broader benefits to cancer care and research. Furthermore, an NCI Center would not only have an enhanced public health benefit, but based on an estimate from the Center for Governmental Research, it would also have a significant economic impact to the region adding nearly 1,900 new jobs, creating $194 million in labor income, and generating $15 million in income and sales tax annually.
Many of us have met individually with the Wilmot team from the University of Rochester to discuss Wilmot’s application, and understand securing this designation remains not only a top University priority, but also continues to garner significant community commitment. It is clear from our discussions that following years of preparation and investment, and consideration of the feedback received from NCI last year, Wilmot is even more equipped with the resources to meet and maintain the rigorous standards for research, education, and cancer prevention and patient care required for NCI designation, and is prepared to capitalize on future opportunities for continued growth. As members of Congress representing upstate New York we are eager for our constituents to realize the benefits of representation by an NCI Center through access to improved research efforts, enhanced prevention programs, and the highest quality subspecialty multidisciplinary cancer care for patients and their families.
Again, we wish to convey our strongest support for an NCI A1 Cancer Center Support Grant for the University of Rochester’s Wilmot Cancer Institute. Thank you for your full consideration of their application. Please feel free to contact any of us with any questions or concerns you may have.
###